Mission
"Provide a new potent brachytherapy tool for the treatment of cancers in humans and animals that will be very effective in improving the lives of these patients."
The Company obtained clarification from the FDA Center for Veterinary Medicine that IsoPet® is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. Vivos is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of IsoPet® to University animal hospitals and private veterinary clinic consortiums.
RadioGel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
draggable-logo
